Clinical Report: CAP Revises Breast and GI Reporting
Overview
The College of American Pathologists (CAP) has updated 14 Cancer Protocols, focusing on breast cancer biomarker reporting and gastrointestinal stromal tumors (GISTs). These revisions align with the latest World Health Organization classifications.
Background
Standardized pathology reporting is crucial for accurate cancer diagnosis, staging, and treatment planning. The updates to CAP protocols reflect ongoing advancements in cancer classification and biomarker testing.
Data Highlights
No numerical or trial data provided in the source material.
Key Findings
- Updated Breast Biomarker Protocol includes revised scoring for estrogen receptor, progesterone receptor, and HER2.
- New accreditation requirement for malignant phyllodes tumors mandates the use of the CAP Breast Phyllodes Tumor protocol.
- Expanded molecular testing options for GISTs now include NTRK fusion gene analysis.
- Structured reporting for GISTs can now be applied to tumors arising at all anatomic sites.
- Revisions are synchronized with WHO and AJCC updates to ensure compliance and standardization.
Clinical Implications
Laboratories must adapt their reporting templates and workflows to incorporate the latest CAP protocol revisions. Reporting templates should align with the updated standards to maintain the quality and accuracy of pathology reports.
Conclusion
The CAP's revisions to cancer protocols are vital for effective patient management.
Related Resources & Content
- CAP, CAP News, 2026 -- CAP Updates Cancer Protocols To Advance Breast Cancer Biomarker Reporting And GIST Molecular Testing
- The ASCO Post, 2026 -- CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
- The Pathologist, 2026 -- Breast Cancer Protocols Move Forward
- The Pathologist, 2026 -- Updated CAP Protocols Explained
- ASCO Publications — Extending the Breast Cancer Surveillance Consortium Model of Invasive Breast Cancer
- CAP Updates Cancer Protocols To Advance Breast Cancer Biomarker Reporting And GIST Molecular Testing - CAP
- CAP Approved Breast.Bmk_1.6.2.0.REL_CAPCP Refe
- CAP Approved GIST_4.4.0.0.REL_CAPCP **Molecula
Based on findings from:
CAP Revises Breast and GI Reporting
The Pathologist, 2026.
https://www.thepathologist.com/issues/2026/articles/september/cap-revises-breast-and-gi-reporting/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
